<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01697306</url>
  </required_header>
  <id_info>
    <org_study_id>CE 70/06</org_study_id>
    <nct_id>NCT01697306</nct_id>
  </id_info>
  <brief_title>The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer</brief_title>
  <official_title>The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus-Calmette Guerin (BCG) Instillation Therapy on the Quality of Life in Non-muscle-invasive Bladder Cancer (NMIBC) Patients: Results of a Prospective, Randomised Phase II Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera San Giovanni Battista</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Turin, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Eastern Piedmont</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Ospedaliera San Giovanni Battista</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To our knowledge, there are no comparative studies on bacillus Calmette-Guerin (BCG) and
      intravesical chemotherapy addressing quality of life (QoL) issues. The aim of this study was
      to prospectively evaluate and compare the QoL of intermediate-risk non-muscle-invasive
      (NMIBC) patients treated with BCG or gemcitabine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intravesical Bacillus Calmette-Guérin (BCG) is considered the most effective agent for
      non-muscle-invasive bladder cancer (NMIBC), representing the first-line option in the
      management of carcinoma in situ (CIS) and high-risk disease. In intermediate-risk NMIBC,
      however, both BCG and intravesical chemotherapy are accepted alternative adjuvant options
      since the superiority of BCG has been only established for disease recurrence but not
      progression and it needs to be balanced against higher toxicity. According to current
      evidence, BCG is considered less tolerable than intravesical chemotherapy such as mitomycin-C
      or doxorubicin, based on reported side effects. Among chemotherapeutic agents, gemcitabine
      has an excellent toxicity profile and promising efficacy in NMIBC patients, including those
      at high-risk of disease recurrence, even if its role on the management of NMIBC has not been
      well-defined yet. To our knowledge, there are no comparative studies on BCG and intravesical
      chemotherapy addressing quality of life (QoL) issues. The aim of this study was to
      prospectively evaluate and compare the QoL of intermediate-risk NMIBC patients treated with
      BCG or gemcitabine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>quality of life of intermediate-risk NMIBC patients treated with intravesical Gemcitabine chemotherapy or BCG</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>comparison of the short term efficacy of the two treatments in terms of recurrence</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of the short term efficacy of the two treatments in terms of progression</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Gemcitabine-arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7-15 days after TUR patients received six weekly instillations of gemcitabine (Gemzar, Eli Lilly SpA), 2.000 mg diluted in 50 cc of saline. Maintenance consisted in monthly instillations up to 1 year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCG-arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7-15 days after TUR patients received an induction cycle of six weekly instillations of Connaught strain Bacillus Calmette-Guerin (BCG Immucyst) 1/3 dose (27 mg) diluted in 50 cc of saline. Maintenance consisted of 3 weekly instillations at 3, 6 and 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine 2 g</intervention_name>
    <description>six weekly instillations of gemcitabine (Gemzar, Eli Lilly SpA), 2.000 mg diluted in 50 cc of saline</description>
    <arm_group_label>Gemcitabine-arm</arm_group_label>
    <other_name>Gemzar, Eli Lilly SpA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCG Vaccine</intervention_name>
    <description>six weekly instillations of Connaught strain BCG (Immucyst) 1/3 dose (27 mg) diluted in 50 cc of saline</description>
    <arm_group_label>BCG-arm</arm_group_label>
    <other_name>BCG Connaught 1/3 dose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with clinical evidence of intermediate-risk non-muscle invasive bladder
             cancer (namely Ta-1, G1-2, multifocal or unique and recurrent, &gt;3 cm in diameter)

          -  WHO performance status ≤2

          -  age ≤85years

          -  BCG naive

          -  patients not treated with intravesical chemotherapy in the last 3 months.

        Exclusion Criteria:

          -  presence of T1G3 or CIS

          -  preoperative urinary cytology positive for high-grade atypia

          -  inadequate bone marrow reserve (white blood cells &lt;3 x 109/l, platelets &lt;100 x 109/l)

          -  history of genito-urinary tuberculosis

          -  presence of uncontrolled urinary infections.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paolo Gontero, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.O.U. San Giovanni Battista Molinette</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>A.O.U. San Giovanni Battista Molinette</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Martínez-Piñeiro JA, Martínez-Piñeiro L, Solsona E, Rodríguez RH, Gómez JM, Martín MG, Molina JR, Collado AG, Flores N, Isorna S, Pertusa C, Rabadán M, Astobieta A, Camacho JE, Arribas S, Madero R; Club Urológico Español de Tratamiento Oncológico (CUETO). Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol. 2005 Oct;174(4 Pt 1):1242-7.</citation>
    <PMID>16145378</PMID>
  </reference>
  <reference>
    <citation>Porena M, Del Zingaro M, Lazzeri M, Mearini L, Giannantoni A, Bini V, Costantini E. Bacillus Calmette-Guérin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study. Urol Int. 2010;84(1):23-7. doi: 10.1159/000273461. Epub 2010 Feb 17.</citation>
    <PMID>20173364</PMID>
  </reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2012</study_first_submitted>
  <study_first_submitted_qc>September 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2012</study_first_posted>
  <last_update_submitted>September 27, 2012</last_update_submitted>
  <last_update_submitted_qc>September 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera San Giovanni Battista</investigator_affiliation>
    <investigator_full_name>Marco Oderda</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>non muscle invasive bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>BCG Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

